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A B S T R AC T
Background. Iron deﬁciency anaemia is common in patients
with non-dialysis-dependent chronic kidney disease (NDDCKD) and is often treated with oral or intravenous (IV) iron
therapy. This trial compared the efﬁcacy and safety of IV iron
isomaltoside 1000 (Monofer®) and oral iron in NDD-CKD patients with renal-related anaemia.
Methods. The trial was a Phase III open-label, comparative,
multicentre, non-inferiority trial conducted in 351 irondeﬁcient NDD-CKD patients, randomized 2:1 to either iron
isomaltoside 1000 (Group A) or iron sulphate administered
as 100 mg elemental oral iron twice daily (200 mg daily) for
8 weeks (Group B). The patients in Group A were randomized
into A1 (infusion of max. 1000 mg single doses over 15 min)
and A2 (bolus injections of 500 mg over 2 min). A modiﬁed
Ganzoni formula was used to calculate IV iron need. The primary end point was change in haemoglobin concentrations
from baseline to Week 4.
Results. Iron isomaltoside 1000 was both non-inferior to oral
iron at Week 4 (P < 0.001) and sustained a superior increase
in haemoglobin from Week 3 until the end of the study at
Week 8 (P = 0.009 at Week 3). The haemoglobin response was
more pronounced with iron isomaltoside 1000 doses ≥1000 mg
(P < 0.05). Serum-ferritin and transferrin saturation concentrations were also signiﬁcantly increased with IV iron. Adverse
drug reactions were observed in 10.5% in the iron isomaltoside
1000 group and 10.3% in the oral iron group. More patients
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treated with oral iron sulphate withdrew from the study due
to adverse events (4.3 versus 0.9%, P = 0.2).
Conclusions. Iron isomaltoside 1000 was more efﬁcacious than
oral iron for increase in haemoglobin and proved to be well tolerated at the tested dose levels in NDD-CKD patients.
Keywords: chronic kidney disease, iron isomaltoside 1000,
iron treatment

INTRODUCTION
Iron deﬁciency is a crucial contributor to anaemia in patients
with non-dialysis-dependent chronic kidney disease (NDDCKD). The KDIGO guidelines recommend either treatment
with intravenous (IV) iron or alternatively 1–3 months of oral
iron therapy in NDD-CKD patients with iron deﬁciency anaemia based on the severity of iron deﬁciency, availability of
venous access, response to prior oral iron therapy, side effects
with prior iron therapy, patient compliance and cost [1]. Oral
iron can be inadequately absorbed in CKD patients [1] and is
often associated with gastrointestinal adverse effects, and therefore IV iron might improve the patient compliance and treatment success [2].
A previous clinical trial of 626 patients with NDD-CKD
and anaemia showed that patients, who were not receiving
erythropoiesis-stimulating agents (ESAs), may beneﬁt from
IV iron treatment targeting a higher ferritin level. Both IV
and oral iron therapy were effective in increasing haemoglobin
(Hb), serum ferritin and transferrin saturation (TSAT) levels,
but the IV iron (ferric carboxymaltose) therapy group with a

higher ferritin target was shown to be superior to oral iron in
delaying and/or reducing the requirement for other anaemia
management as well as producing a faster haematological response with a greater proportion of patients achieving an Hb
increase of ≥1 g/dL [3].
Iron isomaltoside 1000 (Monofer®) is a high-dose IV iron licensed for fast infusion. Iron isomaltoside 1000 has previously
been shown to be safe and well tolerated and to improve markers of iron deﬁciency anaemia in patients with CKD [4],
chronic heart failure [5] and inﬂammatory bowel disease [6].
The aim of this comparative trial was to evaluate the efﬁcacy
and short-term safety of iron isomaltoside 1000 administered as
a single bolus or split bolus injection compared with oral iron
sulphate in patients with NDD-CKD and renal-related anaemia. The primary objective was to compare IV iron isomaltoside 1000 with oral iron sulphate in reducing renal-related
anaemia in patients with NDD-CKD, evaluated as the ability
to increase Hb.
M AT E R I A L S A N D M E T H O D S

Participants
The trial took place at 67 sites (hospitals or private dialysis
clinics) on 3 continents: 17 in India, 10 in Germany, 7 in UK,
7 in Austria, 7 in Russia, 5 in Poland, 4 in Denmark, 3 in
Romania, 3 in USA, 2 in Sweden and 2 in Ireland. Patients
who were ≥18 years of age with estimated glomerular ﬁltration
rate (eGFR) between 15 and 59 mL/min/1.73 m2, Hb <11.0
g/dL, either or both serum ferritin <200 μg/L and TSAT
<20% and had not received ESA treatment within 8 weeks
prior to screening were eligible to participate. The full inclusion
and exclusion criteria are shown in Table 1.
Interventions
Patients were randomized 2:1 to either iron isomaltoside
1000 (Group A) or oral iron sulphate (Group B). The total IV
iron needed for each patient in Group A was calculated according to an adapted Ganzoni formula: cumulative iron dose
(mg) = [body weight (kg) × (13 g/dL − actual Hb (g/dL))] ×
2.4 + depot iron (set at 500 mg) [7]. Patients treated with iron
isomaltoside 1000 either received an IV infusion (Group A1)
of maximum 1000 mg iron isomaltoside 1000 as single doses

Objective and outcomes
The trial was designed with the primary objective to demonstrate non-inferiority of iron isomaltoside 1000 when compared with oral iron. The primary efﬁcacy outcome was
change in Hb concentrations from baseline to Week 4. The
secondary efﬁcacy outcome included change in Hb concentration from baseline to Weeks 2 and 8; change in concentrations
of serum-iron, serum-ferritin, TSAT and total iron-binding
capacity (TIBC) from baseline to Weeks 1, 2, 4 and 8 and
change in total quality-of-life (QoL) score (Linear Analogue
Scale Assessment) from baseline to Weeks 4 and 8. The
LASA questionnaire is a widely used brief measurement
tool, consisting of three questions that evaluate energy level,
daily activity and overall QoL [8].
The safety outcomes of the trial were to determine the number of patients who experienced any adverse drug reaction
(ADR), including any serious adverse reaction (SAR), and
safety laboratory assessments. The nature and causality of the
adverse events and ADRs were objectively assessed by a trial
safety committee. The primary outcome was tested for noninferiority, whereas the remaining outcomes were tested for
superiority.
Sample size and randomization
A stratiﬁed block randomization methodology was used in
the trial to assign patients in a 1:1:1 ratio (2:1 randomization
to Groups A and B) to receive either iron isomaltoside 1000
as 1000 mg infusions (Group A1), or iron isomaltoside 1000
as 500 mg bolus injections (Group A2), or oral iron sulphate
(Group B). The block size was 6. An interactive web response
system (IWRS) was used to randomize the patients. When
the patient data had been entered into the IWRS, a unique randomization number was generated which identiﬁed the treatment the patient was allocated to. The randomization was
stratiﬁed by whether the patients received IV iron treatment
in the past or not and whether the current Modiﬁcation of
Diet in Renal Disease (MDRD) calculated eGFR (women: 175
× (creatinine concentration exp[−1.154]) × (age exp[−0.203])
× 0.742; men: 175 × (creatinine concentration exp[−1.154]) ×
(age exp[−0.203])) [9] was between 15 and 45 mL/min/1.73
m2 or 46 and 59 mL/min/1.73 m2.
The screening and enrolment of the patients were performed by the investigator at the site, whereas the entering
of the patient data into the IWRS generating the randomization number was typically performed by the trial nurse or trial
coordinator.
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Trial design
This prospective, randomized, comparative, open-label,
non-inferiority, multicentre trial was conducted from June
2010 to April 2014. The patients attended seven visits: screening
visit (Visit 1), baseline (Visit 2), four on-treatment and followup visits (Visit 3–6) and one end-of-trial visit (Visit 7) during
an 8-week period.
The protocol and amendments were approved by local ethics
committees/Institutional Review Boards and competent authorities (EudraCT number: 2009-016728-29). The trial was
conducted in accordance with good clinical practice and the
Declaration of Helsinki. The trial was registered at ClinicalTrials.gov (NCT01102413) on 26 March 2010. Written informed
consent was obtained prior to any trial-related activities.

over 15 min (full iron replacement was achieved by one or up
to two doses at a weekly interval) or IV bolus injections (Group
A2) of 500 mg iron isomaltoside 1000 administered over 2 min
once weekly until full replacement dose was achieved. Patients
who received oral iron sulphate (Group B) were treated daily for
8 weeks with 200 mg given as 100 mg twice a day.
During the trial, the patients were prohibited from having
any other iron supplementation, blood transfusion, ESAs and
medications that would potentially yield a decrease in oral
iron absorption.

Table 1. Inclusion and exclusion criteria
Inclusion criteria
• Patients ≥18 years of age with NDD-CKD with MDRD calculated eGFR between 15 and 59 mL/min/1.73 m2
•

Hb <11.0 g/dL (6.80 mmol/L)

•

Either or both of the following iron stores indicators below target (s-ferritin <200 μg/L and TSAT <20%)

•

Life expectancy beyond 12 months by principal investigator’s (PI’s) judgement

•

Willingness to participate after signing informed consent and any authorization as required by local law (e.g. protected health information for North
America)
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Exclusion criteria
• Anaemia predominantly caused by factors other than renal impairment or iron deﬁciency (according to PI’s judgment)
•

Iron overload or disturbances in utilization of iron (e.g. haemochromatosis and haemosiderosis)

•

Drug hypersensitivity (i.e. previous hypersensitivity to iron dextran or iron mono- or disaccharide complexes or iron sulphate or any excipients of the study
drug)

•

History of multiple allergies

•

Decompensated liver cirrhosis or active hepatitis (alanine aminotransferase more than three times upper normal limit)

•

Active acute or chronic infections (assessed by clinical judgement), supplied with white blood cells and C-reactive protein

•

Rheumatoid arthritis with symptoms or signs of active joint inﬂammation

•

Pregnancy or nursing. In order to avoid pregnancy, women had to be post-menopausal (at least 12 months since last menstruation), surgically sterile or
women of child bearing potential must have used one of the following contraceptives during the whole study period and after the study had ended for at least
ﬁve times plasma biological half-life of the investigational medicinal product (5 days): contraceptive pills, intrauterine devices, contraceptive depot injections
(prolonged-release gestagen), subdermal implantation, vaginal ring and transdermal patches

•

Extensive active bleeding necessitating blood transfusion

•

Planned elective surgery during the study

•

Participation in any other clinical study within 3 months prior to screening

•

Known intolerance to oral iron treatment

•

Untreated vitamin B12 or folate deﬁciency

•

IV or oral iron treatment or blood transfusion within 4 weeks prior to screening visit

•

ESA treatment within 8 weeks prior to screening visit

•

s-Ferritin >500 µg/L

•

Any other medical condition that, in the opinion of the PI, may have caused the patient to be unsuitable for the completion of the study or placed the patient at
potential risk from being in the study or interfere with study drug evaluation (e.g. uncontrolled hypertension, unstable ischaemic heart disease or
uncontrolled diabetes mellitus)

•

Body weight <30 kg

Patients and investigators were not blinded to trial medications during the study; however, since the primary outcome was
a laboratory measurement, it was felt that this would not be affected by the open-label trial design.
With a 2:1 randomization, a two-sided signiﬁcance level of
5% and a non-inferiority margin of −0.5 g/dL, there was 80%
power to demonstrate non-inferiority with 214 patients in
Group A and 107 patients in Group B. As the trial was designed
to demonstrate non-inferiority, and it was a requirement that
the analyses of the full analysis set (FAS) and the per protocol
(PP) population should lead to similar conclusions, both analysis sets needed to be powered properly. It was anticipated that
∼10% of patients would have major protocol violations, and so
a total of 350 patients were to be randomized.
No interim analysis of efﬁcacy parameters was performed,
but s-phosphate was analysed when 25, 50 and 100 patients
had been exposed to iron isomaltoside 1000. The analysis of
s-phosphate was not related to the non-inferiority hypothesis,
but only part of monitoring safety in the trial.
Statistical methods
The following data sets were used in the analyses (Figure 1).
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The randomized population (N = 351) included all patients
who were randomized in the trial. The safety population (N =
345) included all patients who were randomized and received at
least one dose of the trial drug. The FAS population (N = 340)
included all patients who were randomized into the trial, received at least one dose of the trial drug and had at least one
post-baseline Hb assessment. The PP population (N = 327) included all patients in the FAS who did not have any major
protocol deviation of clinical or statistical relevance.
The primary efﬁcacy analyses were conducted on FAS and
PP populations, secondary efﬁcacy analyses on the FAS population and the safety analysis was conducted on the safety
population.
The primary efﬁcacy data were tabulated using number,
mean, SD, minimum, maximum and 95% conﬁdence interval
(CI). A mixed model for repeated measures (MMRM) was used
to compare the average change in Hb concentration from
baseline to end-of-study visit with the inclusion of treatment,
visit, treatment × visit interactions, country and stratum
[ past treatment with parenteral iron (yes/no) and current
eGFR between 15 and 45 mL/min/1.73 m2 or 46 and 59 mL/
min/1.73 m2] as factors and baseline Hb as covariate. The
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F I G U R E 1 : Patient disposition.

treatment difference at Week 4 was derived from the interaction
between treatment and visit.
The primary analysis was to assess non-inferiority and the
non-inferiority margin was set as −0.5 g/dL. This margin was
in line with previous studies and was regarded as clinically relevant. If the 95% CI lay entirely above 0, this was considered evidence of superiority in terms of statistical signiﬁcance at the 5%
level. In that case, the P-value associated with a test of superiority was calculated and an evaluation of whether this was sufﬁciently small to reject the hypothesis of no difference was
undertaken. The secondary objectives were to assess other relevant haematology parameters, the effect on QoL and safety.
The MMRM was used to compare the average change in Hb
concentration from baseline to Weeks 2 and 8 with inclusion of
treatment, visit, treatment × visit interactions, country and stratum [ past treatment with parenteral iron (yes/no) and current
eGFR between 15 and 45 mL/min/1.73 m2 or 46 and 59 mL/
min/1.73 m2] as factors and baseline Hb as covariate. The treatment difference at the relevant weeks was derived from the
interaction between treatment and visit. The same method
was followed to compare the between-treatment group change

in serum-iron, serum-ferritin, TSAT and TIBC from baseline to
Week 1, 2, 4 or 8 and in QoL score from baseline to Week 4 or 8.
The baseline characteristics and safety data were displayed
descriptively. All tests were two tailed and the signiﬁcance
level was 0.05.
R E S U LT S
Patients
A total of 743 patients were screened in the period 30 June
2010 to 24 February 2014 of whom 351 patients were randomized 2:1 into Group A (233 patients) and Group B (118 patients). Group A was further divided into subgroups A1
(infusion dose, 117 patients) and A2 (split dose, 116 patients).
The last patient’s last visit was 25 April 2014.
Out of the 351 patients enrolled, 314 (89.5%) patients completed the trial and 37 (10.5%) patients discontinued. The details of patient disposition are summarized in Figure 1.
The patient demographics and baseline characteristics are
summarized in Table 2 and baseline laboratory parameters
are shown in Table 3. Overall baseline characteristics in Groups
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A and B were comparable between the treatment groups
(Tables 2 and 3). For patients in Group A, the gender distribution was 39.5% men and 60.5% women, and mean (SD) age was
Table 2. Summary of baseline demographics for treatment allocation
(randomized population)
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Statistics/category

Age (years)
n
Mean (SD)
Median
(min.:max.)
Gender, n (%)
Men
Women
Ethnic origin, n (%)
Caucasian
Black
Asian
Others
BMI (kg/m2)
n
Mean (SD)
Median
(min.:max.)

58 (16) years, Hb 9.67 (1.13) g/dL, serum ferritin 94.99 (112.79)
µg/L, TSAT 18.10 (27.45) % and eGFR 27.06 (10.66) mL/min/
1.73 m2. In Group B, the data were 54.2% men and 45.8%
women, age 58 (16) years, Hb 9.64 (1.05) g/dL, serum ferritin
98.81 (90.19) µg/L, TSAT 15.51 (7.76) % and eGFR 27.05
(10.50) mL/min/1.73 m2.

Treatment group
Iron
Iron sulphate
isomaltoside
(n = 118)
1000 (n = 233)

Overall
(N = 351)

232
57.63 (15.54)
58.00 (22:93)

118
57.94 (16.34)
57.50 (20:90)

350
57.73 (15.79)
58.00 (20:93)

92 (39.5)
141 (60.5)

64 (54.2)
54 (45.8)

156 (44.4)
195 (55.6)

87 (37.3)
–
139 (59.7)
6 (2.6)

47 (39.8)
1 (0.8)
64 (54.2)
6 (5.1)

134 (38.2)
1 (0.3)
203 (57.8)
12 (3.4)

232
25.80 (6.66)
24.86
(13.33:52.23)

118
25.27 (6.60)
24.55
(13.92:51.68)

350
25.62 (6.64)
24.81
(13.33:52.23)

Exposure to iron
In Group A1, 116 patients were dosed with iron isomaltoside
1000 at baseline (mean ± SD: 884 ± 125 mg, range: 750–1000
mg) and 9 were dosed again at Week 1 (306 ± 110 mg, range:
250–500 mg). In Group A2, 112 patients were dosed with
iron isomaltoside 1000 at baseline (506 ± 53 mg, range: 440–
1000 mg), 107 patients were dosed again at Week 1 (393 ±
138 mg, range: 250–1000 mg) and 16 patients were dosed
again at Week 2 (313 ± 112 mg, range: 250–500 mg). In
Group B, 117 patients were dosed with 200 mg iron sulphate
daily for 8 weeks (11 200 mg in total). There were minor protocol deviations regarding the dosing regimen. If the administered dose was not exactly the calculated dose but was within
the range 80–120%, this was regarded as a minor deviation,
whereas if the administered dose was outside this range, it
was considered as a major deviation and the patient was excluded from the PP analysis.

Table 3. Baseline laboratory parameters, FAS
Statistics/category

Hb (g/dL)
n
Mean (SD)
Median (min.:max.)
Serum iron (µmol/L)
n
Mean (SD)
Median (min.:max.)
Serum ferritin (µg/L)
n
Mean (SD)
Median (min.:max.)
TSAT (%)
n
Mean (SD)
Median (min.:max.)
TIBC (µmol/L)
n
Mean (SD)
Median (min.:max.)
eGFR (mL/min/1.73 m2)
n
Mean (SD)
Median (min.:max.)
C-reactive protein (mg/L)
n
Mean (SD)
Median (min.:max.)

Treatment group
Iron isomaltoside 1000 infusion
(n = 114)

Iron isomaltoside 1000 bolus
(n = 110)

All iron isomaltoside 1000
(n = 224)

Iron sulphate
(n = 116)

114
9.73 (1.09)
9.90 (6.5:12.1)

110
9.60 (1.17)
9.80 (5.2:11.7)

224
9.67 (1.13)
9.80 (5.2:12.1)

116
9.64 (1.05)
9.80 (6.7:11.5)

114
11.23 (18.82)
8.86 (0.5:196.0)

110
9.63 (6.86)
8.77 (1.8:65.5)

224
10.44 (14.26)
8.77 (0.5:196.0)

116
8.93 (4.01)
8.59 (1.8:23.8)

114
80.18 (114.33)
47.30 (3.0:955.4)

110
110.35 (109.58)
79.05 (3.6:609.3)

224
94.99 (112.79)
60.85 (3.0:955.4)

116
98.81 (90.19)
78.95 (3.1:550.0)

114
19.20 (36.79)
13.56 (0.7:388.0)

110
16.97 (11.67)
15.56 (3.0:99.5)

224
18.10 (27.45)
14.38 (0.7:388.0)

116
15.51 (7.76)
14.00 (2.5:39.7)

114
61.71 (13.62)
59.52 (38.1:105.8)

110
57.08 (13.42)
54.06 (34.7:111.2)

224
59.44 (13.69)
56.74 (34.7:111.2)

116
57.70 (13.93)
56.47 (28.5:108.5)

114
26.77 (10.64)
23.00 (15:57)

110
27.35 (10.72)
24.00 (15:56)

224
27.06 (10.66)
24.00 (15:57)

116
27.05 (10.50)
24.00 (15:58)

114
8.64 (30.76)
3.00 (0.20:316.68)

110
9.38 (15.83)
3.60 (0.20:100.74)

224
9.00 (24.54)
3.16 (0.20:316.68)

116
8.55 (13.31)
3.36 (0.22:80.0)

Conversion factor for serum iron: µmol/L/0.179 = µg/dL.
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Table 4. Laboratory parameters: estimated effect size and its precision, Group A versus B
Laboratory parameter, time point (number of
patients)

Iron sulphate (Group B),
least-square mean
estimatea

Difference estimates
(95% CI)

P value

0.33
0.60
0.94

0.27
0.37
0.49

0.059 (−0.11; 0.23)
0.22 (0.012; 0.43)
0.45 (0.20; 0.69)

0.49
<0.001/0.039b
<0.001

0.61

0.39

0.22 (0.003; 0.43)

<0.001/0.047b

6.22
4.05
2.89
2.81

2.66
2.02
1.99
1.86

3.55 (1.80; 5.31)
2.03 (0.72; 3.34)
0.90 (−0.31; 2.10)
0.95 (−0.16; 2.06)

<0.001
0.003
0.14
0.091

321 (270; 373)
335 (252; 418)
235 (170; 301)
156 (105; 206)

<0.001
<0.001
<0.001
<0.001

8.37 (5.17; 11.57)
6.20 (3.86; 8.54)
4.77 (2.45; 7.08)
3.20 (1.06; 5.33)

<0.001
<0.001
<0.001
0.004

−3.92 (−5.43; −2.41)
−5.18 (−7.01; −3.36)
−7.16 (−8.99; −5.32)
−4.78 (−6.35; −3.20)

<0.001
<0.001
<0.001
<0.001

353
387
289
222

32
52
54
66

11.01
8.34
7.34
6.73

2.64
2.14
2.57
3.54

−4.64
−7.52
−9.85
−9.97

−0.72
−2.33
−2.70
−5.19

Conversion factor for serum iron: µmol/L/0.179 = µg/dL.
a
Least-square means from repeated measures model with treatment, visit, treatment × visit interactions, country and stratum [past treatment with parenteral iron (yes/no) and current eGFR
between 15 and 45 mL/min/1.73 m2 or 46 and 59 mL/min/1.73 m2] as factors and baseline Hb as covariate.
b
The ﬁrst P-value represents the non-inferiority test and the second P-value represents the superiority test.

Efﬁcacy results
Change in Hb concentration. The primary analysis (change
in Hb from baseline to Week 4) was conducted on the FAS
(N = 340) and PP analysis set (N = 327).
The test for non-inferiority showed that iron isomaltoside
1000 was non-inferior to iron sulphate in its ability to increase
Hb from baseline to Week 4 in both the FAS and PP data sets
(FAS—difference estimate: 0.22, 95% CI: 0.012; 0.43, P < 0.001;
PP—difference estimate: 0.22, 95% CI: 0.003; 0.43, P < 0.001)
(Table 4, Figure 2). Similar results were observed when the
iron isomaltoside 1000 infusion and bolus subgroups (Groups
A1 and A2) were compared with the iron sulphate group
(Group B) in both FAS and PP data sets. For the FAS, the difference estimate for A1 versus B was 0.27, 95% CI: 0.015; 0.53,
P < 0.001, and for A2 versus B, it was 0.17, 95% CI: −0.055;
0.39, P < 0.001. For the PP data set, the difference estimate for
A1 versus B was 0.27, 95% CI: 0.007; 0.54, P < 0.001, and for A2
versus B, it was 0.16, 95% CI: −0.066; 0.39, P < 0.001 (Supplementary Tables S1 and S2). In addition, iron isomaltoside 1000 showed
superiority over iron sulphate in terms of a signiﬁcantly higher
increase in Hb concentration from baseline to Week 4 (FAS: P =
0.039; PP: P = 0.047). A similar result was observed when Group
A1 was compared with Group B, whereas there was no superiority
between Groups A2 and B (Supplementary Tables S1 and S2).
There was a statistically signiﬁcant larger increase in Hb concentration from baseline to Week 8 within Group A compared

with Group B (P < 0.001) (Table 4 and Figure 3). Similar results
were observed when Groups A1 and A2 were compared with
Group B (Supplementary Tables S1 and S2).
An exploratory analysis showed that the signiﬁcantly superior
increase in Hb concentration with iron isomaltoside 1000 compared with oral iron sulphate was sustained from Week 3 until
Week 8 with a gradual increase throughout Weeks 1–8 (Figure 3).
In addition, the Hb response was more pronounced with iron
isomaltoside 1000 doses of 1000 mg or greater (Figure 4).
Change in other laboratory parameters. Secondary outcomes included change in other laboratory parameters and
this was conducted on the FAS (N = 340).
The estimated effect size for the laboratory parameters, including precision, is shown for Group A compared with B in
Table 4, Group A1 compared with B in Supplementary Table S1
and Group A2 compared with B in Supplementary Table S2.
Change in concentrations of serum-iron, serum-ferritin,
TSAT and TIBC. There was a statistically signiﬁcant larger
increase in serum iron concentration from baseline to Week 1
and Week 2 in Group A compared with Group B (Week 1: P <
0.001; Week 2: P = 0.003) (Table 4). Similar results were observed when Group A1 was compared with Group B (Supplementary Table S1) and when Group A2 was compared with
Group B at Week 2 (Supplementary Table S2).
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Hb (g/dL)—FAS
Week 2 (Group A: 210, Group B: 110)
Week 4 (Group A: 209, Group B: 108)
Week 8 (Group A: 210, Group B: 112)
Hb (g/dL)—PP analysis set
Week 4 (Group A: 204, Group B: 106)
Serum iron (µg/dL)—FAS
Week 1 (Group A: 217, Group B: 109)
Week 2 (Group A: 209, Group B: 110)
Week 4 (Group A: 208, Group B: 108)
Week 8 (Group A: 209, Group B: 112)
Serum ferritin (ng/mL)—FAS
Week 1 (Group A: 217, Group B: 109)
Week 2 (Group A: 209, Group B: 110)
Week 4 (Group A: 208, Group B: 108)
Week 8 (Group A: 209, Group B: 112)
TSAT (%)—FAS
Week 1 (Group A: 217, Group B: 109)
Week 2 (Group A: 209, Group B: 110)
Week 4 (Group A: 208, Group B: 108)
Week 8 (Group A: 209, Group B: 112)
TIBC (µmol/L)—FAS
Week 1 (Group A: 217, Group B: 109)
Week 2 (Group A: 209, Group B: 110)
Week 4 (Group A: 208, Group B: 108)
Week 8 (Group A: 209, Group B: 112)

Iron isomaltoside 1000
(Group A), least-square
mean estimatea
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F I G U R E 2 : Change in Hb from baseline to Week 4.

There was a statistically signiﬁcant larger increase in serumferritin concentration and TSAT, and larger decrease in TIBC,
from baseline to Weeks 1, 2, 4 and 8 in Group A compared with
Group B (P < 0.001 for serum ferritin and TIBC at all time
points and for TSAT at Weeks 1–4; P = 0.004 for TSAT at
Week 8) (Table 4 and Figure 3). Similar results were observed
for all iron parameters when Groups A1 and A2 were compared
with Group B (Supplementary Tables S1 and S2).
Change in total QoL. The change in QoL (secondary outcomes) was assessed in the FAS (N = 340).
There was a statistically signiﬁcant improvement in QoL (energy level, ability to do daily activities and overall QoL) from
baseline to Week 8 within each treatment group. The improvement in QoL was similar in Groups A and B and there were no
statistical difference between them (Supplementary Table S3).
Safety
All safety analyses were conducted on the safety analysis set
(N = 345).
There was no statistical signiﬁcant difference in the proportion of patients experiencing an adverse event (AE) between
Groups A and B [Group A: 95/228 (41.7%); Group B: 53/117
(45.3%)] (Table 5). There were a total of 86 treatment emergent
AEs in 39/116 patients (33.6%) in Group A1 and 100 treatment
emergent AEs in 56/112 patients (50.0%) in Group A2 (P = 0.02).
The main reason for this difference was a higher frequency of
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pyrexia and infections such as gastroenteritis, rhinitis and
respiratory tract infections in Group A2 patients.
In relation to severity, causality and outcome, the AEs were
comparable between the groups, and the majority of the AEs
were mild or moderate and unrelated to the trial drug as adjudged by the trial safety committee after review of the temporal
relationship of the AE with iron dosing as well as the comments
of the local principal investigator.
ADRs (i.e. treatment-related AEs) were observed in 24/228
(10.5%) of the patients in Group A and in 12/117 (10.3%) of
the patients in Group B. No dose relationship was found. A
total of 14 ADR events were classiﬁed as related to trial therapy
in 10/116 (8.6%) patients in Group A1 and there were 19 events
in 14/112 (12.5%) patients in Group A2. There was no signiﬁcant difference in the number of ADRs between Groups A1 and
A2 (P = 0.39).
Three SARs [two events of hypersensitivity in Group A
(2/228, 0.9%) and one event of oesophagitis in Group B
(1/117, 0.9%)] were reported. The ﬁrst event of hypersensitivity
occurred during the ﬁrst exposure to iron isomaltoside 1000 in
a patient with a medical history of ischaemic heart disease. The
patient had a marked decrease in blood pressure which required
treatment with atropine and adrenaline. The other hypersensitivity event occurred in a patient during the second administration of iron isomaltoside 1000 after the ﬁrst dosage had been
well tolerated. No hypotension was reported in this patient
and the patient recovered following treatment with steroid
only. Both patients fully recovered from the events.
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F I G U R E 3 : Hb, serum ferritin, TSAT and TIBC over time by treatment group.

There were three fatal events during the study, all occurring
in patients in Group A. None of the fatal events were related to
iron isomaltoside 1000, and all three subjects had a signiﬁcant
prior history of cardiac disease. Two 82-year-old men died of
decompensated heart failure 3 months and 6 weeks, respectively, after receiving the study drug [one had previous myocardial
infarction (MI), diabetes, heart failure and peripheral vascular
bypass; the other patient had previous heart failure and ventricular arrhythmias]. An 84-year-old woman with previous
coronary bypass, pacemaker and diabetes developed pneumonia and died of MI 6 days after an iron bolus treatment.
More patients treated with oral iron sulphate were withdrawn from the study due to AEs (5/117, 4.3%) than patients
treated with iron isomaltoside 1000 (2/228, 0.9%).
Transient hypophosphataemia ( phosphate <2 mg/dL) was
reported in ﬁve patients [Group A1: 3/116 (2.6%); Group A2:

1/112 (0.9%); Group B: 1/117 (0.9%)]. The three patients in
Group A1 had a phosphate level of 1.2, 1.7 and 1.8 mg/dL,
and both patients in Groups A2 and B had a phosphate level
of 1.2 mg/dL. None of these hypophosphataemic events were
reported as AEs.

DISCUSSION
The objective of the trial was to evaluate the efﬁcacy and shortterm safety of IV iron isomaltoside 1000 administered by infusions or repeated bolus injections in comparison with oral iron
sulphate in NDD-CKD patients with renal-related anaemia.
Iron sulphate was selected as the comparator in this study
since it has been widely used in the treatment of iron deﬁciency
anaemia in previous studies in CKD patients [10, 11]. In the
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F I G U R E 4 : Hb over time by dose, mean (±SD) baseline Hb was 10.09 ± 1.03, 9.56 ± 0.92, 8.39 ± 1.13 and 9.64 ± 1.05 g/dL for patients treated

with <1000 mg, 1000 mg, >1000 mg iron isomaltoside 1000 and oral iron sulphate, respectively.
Table 5. Summary of adverse events for iron isomaltoside 1000 (infusion and bolus dose) and iron sulphate, safety population
Number of patients

Iron isomaltoside 1000,
infusion (n = 116)

Iron isomaltoside 1000, bolus
(n = 112)

Iron sulphate (n = 117)

Adverse events, n (%)
ADR, n (%)
Serious adverse events, n (%)
Serious ADRs, n (%)
Suspected unexpected SAR, n (%)
Withdrawals due to adverse events

39 (33.6)
10 (8.6)
6 (5.2)
1 (0.9)
–
1 (0.9)

56 (50.0)
14 (12.5)
6 (5.4)
1 (0.9)
–
1 (0.9)

53 (45.3)
12 (10.3)
10 (8.5)
1 (0.9)
–
5 (4.3)

present trial, IV iron isomaltoside 1000 was not only noninferior but also superior to iron sulphate in achieving the primary outcome. It induced a signiﬁcantly higher increase in the
level of Hb from baseline to Week 4 than twice daily administration of 100 mg iron sulphate, and this was sustained over an
8-week treatment period. This indicates a greater efﬁcacy of iron
isomaltoside 1000 over oral iron. The superior effect was sustained from Week 3 and until the end of the study at Week
8. Furthermore, the Hb response was more pronounced with
iron isomaltoside 1000 doses ≥1000 mg. Similar results have
been observed in other recent studies with CKD patients [10,
11]. In the study by Qunibi et al. [11], IV ferric carboxymaltose
was found to induce a signiﬁcantly higher increase in Hb when
compared with oral iron over an 8-week treatment period in
NDD-CKD patients, and in a study by Spinowitz et al. [10],
IV ferumoxytol led to a signiﬁcantly higher increase in Hb
from baseline to Day 35 when compared with oral iron in
CKD patients. Both of these studies utilized higher cumulative
mean doses of IV iron than were administered in our trial and
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allowed patients to be on an ESA, whereas in our trial,
NDD-CKD patients were ESA naive. At the current time, the
optimal Hb target for NDD-CKD patients who are not receiving an ESA has yet to be established and this issue merits further
investigation.
In the present trial, there was a statistically signiﬁcant increase
in serum ferritin and TSAT concentration and a decrease
in TIBC concentration from baseline to Week 8 in patients
treated with iron isomaltoside 1000. These results potentially
signify a faster repletion of body iron stores with administration
of iron isomaltoside 1000 than with iron sulphate, an effect
also noted in the trial by Qunibi et al. [11] with IV ferric
carboxymaltose.
Even though there was a statistically signiﬁcant improvement in QoL within each treatment group, there was no difference between patients treated with either iron isomaltoside
1000 or oral iron sulphate. Thus, the clinical effect of the statistically higher increase in Hb and iron-related parameters related to the IV iron treatment needs to be evaluated further; it is
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unknown whether an increase in Hb of <1 g/dL will have any
effect on QoL.
The majority of the AEs in both treatment groups were mild
or moderate and unrelated to the trial drug. The frequency of
ADRs was comparable between the treatment groups (10.5 versus 10.3%). Three SARs (two events of hypersensitivity in
Group A and one event of oesophagitis in Group B) were reported. Both patients recovered from the hypersensitivity
events. Although there were three fatal events, these were due
to cardiac events and all occurred in patients with prior signiﬁcant cardiac disease, there being no relationship with the study
drug. The safety ﬁndings were comparable with other trials investigating iron isomaltoside 1000 that have shown a good
safety proﬁle in CKD patients [4, 12, 13].
More patients treated with oral iron sulphate were withdrawn
from the study due to AEs than patients treated with iron isomaltoside 1000 (4.3 versus 0.9%). One limitation was that the modiﬁed MDRD formula for Asian ethnicity was not utilized within
the study; it is recognized that the standard MDRD formula will
over-estimate eGFR in Asians and this may have been the case in
this study. However, the mean eGFR and the proportion of Asian
and European patients were very similar between the treatment
groups. Although no speciﬁc ethnicity subgroup analysis was
performed to assess whether changes in Hb or iron parameters
were different between Asians and Europeans, the country in
which patients were recruited was included in the multi-variable
analysis, and hence, we feel that the study results are generalizable
to a wide multiracial population.
In conclusion, this randomized trial demonstrated that iron
isomaltoside 1000 is superior to oral iron sulphate in its ability
to increase Hb over an 8-week period. Markers of iron deﬁciency were also signiﬁcantly improved. The safety proﬁle of
iron isomaltoside 1000 was comparable with oral iron sulphate
in patients with NDD-CKD and renal-related anaemia, but
more patients stopped oral therapy due to side effects.

